KTRA 2x Phase two drugs data due soon.

NASDAQ:KTRA   Kintara Therapeutics, Inc.
100m shelf popped out of the blue, now in effect. Phase two data is due and looks to be positive. Cap is under 60m. Seems very undervalued here. The shelf is strange because the CEO has stated that they had enough cash to get through Q4/21, so why the offering now?

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.